Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 31, 2022 1:33pm
167 Views
Post# 35060622

RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboRepost:

.. a true tumor-killer combo that would not be effective without each other.

Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment induced strong tumor regression and prolonged survival compared to each treatment option individually.

Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death.


https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/
<< Previous
Bullboard Posts
Next >>